These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 18094214)

  • 1. Commentary on the clinical relevance of concentration/QTc relationships for new drug candidates.
    Bloomfield D; Krishna R
    J Clin Pharmacol; 2008 Jan; 48(1):6-8. PubMed ID: 18094214
    [No Abstract]   [Full Text] [Related]  

  • 2. A perspective on the use of concentration-QT modeling in drug development.
    Russell T; Riley SP; Cook JA; Lalonde RL
    J Clin Pharmacol; 2008 Jan; 48(1):9-12. PubMed ID: 18094215
    [No Abstract]   [Full Text] [Related]  

  • 3. Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review.
    Garnett CE; Beasley N; Bhattaram VA; Jadhav PR; Madabushi R; Stockbridge N; Tornøe CW; Wang Y; Zhu H; Gobburu JV
    J Clin Pharmacol; 2008 Jan; 48(1):13-8. PubMed ID: 18094216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 guideline.
    Darpo B; Nebout T; Sager PT
    J Clin Pharmacol; 2006 May; 46(5):498-507. PubMed ID: 16638733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. If a drug deemed 'safe' in nonclinical tests subsequently prolongs QT in phase 1 studies, how can its sponsor convince regulators to allow development to proceed?
    Shah RR
    Pharmacol Ther; 2008 Aug; 119(2):215-21. PubMed ID: 18455801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statistical issues including design and sample size calculation in thorough QT/QTc studies.
    Zhang J; Machado SG
    J Biopharm Stat; 2008; 18(3):451-67. PubMed ID: 18470755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statistical assessment of QT/QTc prolongation based on maximum of correlated normal random variables.
    Cheng B; Chow SC; Burt D; Cosmatos D
    J Biopharm Stat; 2008; 18(3):494-501. PubMed ID: 18470758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ICH E14 Q&A(R2) document: commentary on the further updated recommendations on thorough QT studies.
    Shah RR; Morganroth J; Kleiman RB
    Br J Clin Pharmacol; 2015 Mar; 79(3):456-64. PubMed ID: 25060671
    [No Abstract]   [Full Text] [Related]  

  • 9. Assessing proarrhythmic potential of drugs when optimal studies are infeasible.
    Rock EP; Finkle J; Fingert HJ; Booth BP; Garnett CE; Grant S; Justice RL; Kovacs RJ; Kowey PR; Rodriguez I; Sanhai WR; Strnadova C; Targum SL; Tsong Y; Uhl K; Stockbridge N
    Am Heart J; 2009 May; 157(5):827-36, 836.e1. PubMed ID: 19376308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sample size calculations in thorough QT studies.
    Zhang L; Dmitrienko A; Luta G
    J Biopharm Stat; 2008; 18(3):468-82. PubMed ID: 18470756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. QT as a safety biomarker in drug development.
    Whellan DJ; Green CL; Piccini JP; Krucoff MW
    Clin Pharmacol Ther; 2009 Jul; 86(1):101-4. PubMed ID: 19474784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drugs, QTc interval prolongation and final ICH E14 guideline : an important milestone with challenges ahead.
    Shah RR
    Drug Saf; 2005; 28(11):1009-28. PubMed ID: 16231954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Drug-induced long QT syndrome].
    Kishida H
    Nihon Rinsho; 2007 Oct; 65 Suppl 8():426-9. PubMed ID: 18074575
    [No Abstract]   [Full Text] [Related]  

  • 14. The US Food and Drug Administration Cardiorenal Advisory Panel and the drug approval process.
    Roden DM; Temple R
    Circulation; 2005 Apr; 111(13):1697-702. PubMed ID: 15811869
    [No Abstract]   [Full Text] [Related]  

  • 15. Use of ANOVA to estimate inter- and intra-reader variability for a group of readers in thorough QT/QTc studies.
    Natekar M; Mahajan V; Satra A; O'Kelly M; Karnad DR
    Clin Pharmacol Ther; 2008 Mar; 83(3):489-91. PubMed ID: 18183035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identifying patients at risk for QT interval prolongation: case studies.
    Flyer JL
    J Fam Pract; 2005 Jun; Suppl():S18-9. PubMed ID: 15938991
    [No Abstract]   [Full Text] [Related]  

  • 17. Improving the in Vivo QTc assay: The value of implementing best practices to support an integrated nonclinical-clinical QTc risk assessment and TQT substitute.
    Vargas HM; Rossman EI; Wisialowski TA; Nichols J; Pugsley MK; Roche B; Gintant GA; Greiter-Wilke A; Kleiman RB; Valentin JP; Leishman DJ
    J Pharmacol Toxicol Methods; 2023; 121():107265. PubMed ID: 36997076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discontinued drugs in 2010: cardiovascular drugs.
    Zhao HP; Zhang XS; Xiang BR
    Expert Opin Investig Drugs; 2011 Oct; 20(10):1311-25. PubMed ID: 21870899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Model-based evaluation of QTc interval risk: an increasing emphasis on early decision making.
    Krishna R
    J Clin Pharmacol; 2009 Sep; 49(9):1010-1. PubMed ID: 19717724
    [No Abstract]   [Full Text] [Related]  

  • 20. [The side effects of anti-arrhythmia medications].
    Eränen J
    Duodecim; 1995; 111(24):2406-12. PubMed ID: 9841192
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.